VALIANT at 1 Year: Pegcetacoplan Kept Proteinuria Down in C3 Glomerulopathy and Primary IC-MPGN
The 26-week open-label period of the phase 3 VALIANT trial, now published in JASN, shows that the proteinuria reduction seen with pegcetacoplan at week 26 was maintained through week 52 in C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). Patients